JAK Inhibition in the Aicardi-Goutières Syndrome.

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Copyright JAK Inhibition in the Aicardi–Goutières Syndrome Bénédicte Neven, Buthaina Al Adba, Marie Hully, Isabelle Desguerre, Claire Pressiat, Natalie Boddaert, Darragh Duffy, Gillian Rice, Luis Seabra, Marie-Louise Frémond, et al.

[1]  A. Vanderver,et al.  Janus Kinase Inhibition in the Aicardi-Goutières Syndrome. , 2020, The New England journal of medicine.

[2]  A. Vanderver,et al.  Development of a neurologic severity scale for Aicardi Goutières Syndrome. , 2020, Molecular genetics and metabolism.

[3]  M. Bouxsein,et al.  Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. , 2019, Endocrine reviews.

[4]  Y. Crow,et al.  Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency , 2018, Annals of the rheumatic diseases.

[5]  Y. Crow,et al.  Reverse-Transcriptase Inhibitors in the Aicardi–Goutières Syndrome , 2018, The New England journal of medicine.

[6]  W. Gozansky,et al.  Bisphosphonate Drug Holiday and Fracture Risk: A Population‐Based Cohort Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  Y. Crow,et al.  An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation , 2018, Neurology.

[8]  A. Moser,et al.  Neonatal detection of Aicardi Goutières Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots. , 2017, Molecular genetics and metabolism.

[9]  F. Rieux-Laucat,et al.  Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. , 2016, The Journal of allergy and clinical immunology.

[10]  K. Michaëlsson,et al.  Mortality After Atypical Femoral Fractures: A Cohort Study , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.